Vadivarhe Speci.
NSE: VSCL · Specialty Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vadivarhe Speci.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vadivarhe Speciality Chemicals Ltd is an Indian manufacturer specialising in the production and supply of speciality chemicals, APIs, and drug intermediates. The company serves a diverse range of sectors including pharmaceuticals, personal care, and organic chemical synthesis.
Business Model
The company operates as a manufacturer and supplier, generating revenue through the production of custom synthesis chemicals and bulk drugs for global markets.
Growth Outlook
Growth is driven by the company's focus on custom synthesis and its broad portfolio of chemical intermediates catering to the pharmaceutical and personal care industries.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight regarding environmental standards and pharmaceutical manufacturing practices.
- Raw Material Price Volatility. Fluctuations in the cost of chemical feedstocks and raw materials can significantly impact operating margins.
- Market Competition. The speciality chemicals sector is highly competitive, requiring continuous investment in R&D to maintain market share.
- Foreign Exchange Risk. As a globally active producer, the company is exposed to currency fluctuations that may affect export profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Vadivarhe Speci. and 5,000+ companies — free.
Peers · Specialty Chemicals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Vadivarhe Speci.VSCL | ₹30 Cr | — | — | — | 1.8% | — | — | -27.1% |
Black Rose IndusBLACKROSE | ₹586 Cr | 19.65 | 13.25 | -0.2% | 12.5% | 17.8% | 23.9% | +10.3% |
Vipul OrganicsVIPULORG | ₹506 Cr | 55.50 | 28.24 | 16.8% | 10.4% | 9.0% | 13.0% | +26.1% |
Plastiblends India LimitedPLASTIBLEN | ₹487 Cr | 11.78 | 6.76 | 5.5% | 9.2% | 9.7% | 12.8% | +4.3% |
Agastya Energy and Infrastructure LimitedSANGINITA | ₹455 Cr | -19.81 | -83.28 | -23.2% | -3.2% | -18.0% | -14.1% | +581.9% |
Aarti SurfactantAARTISURF | ₹449 Cr | 22.93 | 9.64 | 25.2% | 6.1% | 7.7% | 12.4% | +7.3% |
As of Mar 2026
Financials
Vadivarhe Speci.
NSE: VSCL · Specialty Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vadivarhe Speci.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vadivarhe Speciality Chemicals Ltd is an Indian manufacturer specialising in the production and supply of speciality chemicals, APIs, and drug intermediates. The company serves a diverse range of sectors including pharmaceuticals, personal care, and organic chemical synthesis.
Business Model
The company operates as a manufacturer and supplier, generating revenue through the production of custom synthesis chemicals and bulk drugs for global markets.
Growth Outlook
Growth is driven by the company's focus on custom synthesis and its broad portfolio of chemical intermediates catering to the pharmaceutical and personal care industries.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight regarding environmental standards and pharmaceutical manufacturing practices.
- Raw Material Price Volatility. Fluctuations in the cost of chemical feedstocks and raw materials can significantly impact operating margins.
- Market Competition. The speciality chemicals sector is highly competitive, requiring continuous investment in R&D to maintain market share.
- Foreign Exchange Risk. As a globally active producer, the company is exposed to currency fluctuations that may affect export profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Vadivarhe Speci. and 5,000+ companies — free.
Peers · Specialty Chemicals
As of Mar 2026